DOI: 10.1055/s-00000020

Geburtshilfe und Frauenheilkunde

References

Doi T, Shitara K, Naito Y. et al.
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.

Lancet Oncol 2017;
18: 1512-1522

Download Bibliographical Data

Search in:
Access: